:: Volume 25, Issue 6 (Bimonthly 2021) ::
Feyz 2021, 25(6): 1294-1302 Back to browse issues page
Evaluation of antioxidant effects of harmaline in NMRI diabetic male mice
Maryam Yaghoubi , Hanieh Jafary , Parichehreh Yaghmaei
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, I.R. Iran. , h-jafary@srbiau.ac.ir
Abstract:   (1375 Views)
Background: Diabetes is a metabolic disease that can causes complications such as oxidative stress and decreased levels of antioxidant enzymes. In researches, it has been found that the alcoholic extract of pecan is effective in the treatment of diabetes. Harmaline is an alkaloid of pecan extract, which has antioxidant properties. In this study, models of type 1 diabetic mice were used to evaluate the properties of harmaline.
Materials and Methods: In this study, 40 male NMRI mice were used. Mice were divided into 5 groups of eight including control (ordinary food and water recipient), diabetic (mice that became diabetic with streptozotocin), sham (diabetic mice received only the solvent of harmalin, distilled water, during the experimental stages), experimental groups 1(50 mg/kg harmaline) and 2 (100 mg/kg harmaline). At the end of the harmaline treatment period, the animals were anesthetized with ether and blood samples were taken from all groups. Glucose, insulin, lipid profile, malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) were measured in rat serum. Sampling of pancreatic tissue was performed using western blotting method to measure insulin changes in experimental groups.
Results: The levels of insulin, HDL, superoxide dismutase and catalase in treatment groups had a significant increase and the levels of glucose, MDA, LDL and cholesterol in treatment groups showed a significant decrease.
Conclusion: Treatment of mice with harmaline can improves the condition of diabetic animals.
Keywords: Harmaline, Antioxidant, Diabetes, Antioxidant enzyme
Full-Text [PDF 389 kb]   (547 Downloads)    
Type of Study: Research | Subject: General
Received: 2021/03/31 | Revised: 2023/11/1 | Accepted: 2021/11/3 | Published: 2022/02/1
References
1. Ling S, Zaccardi F, Lawson C, Seidu SI, Davies MJ, Khunti K. Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Diabetes care 2021; 44(4): 915-24.
2. Dashora U, Patel DC, Gregory R, Winocour P, Dhatariya K, Rowles S, Macklin A, Rayman G, Nagi D. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020). Diabetic medicine : a journal of the British Diabetic Association 2021; 38(2): e14458.
3. Khan FA, Maalik A, Iqbal Z, Malik I. Recent pharmacological developments in beta-carboline alkaloid "harmaline". European journal of pharmacology 2013; 721(1-3): 391-94
4. Nafisi S, Bonsaii M, Maali P, Khalilzadeh MA, Manouchehri F. Beta-carboline alkaloids bind DNA. Journal of photochemistry and photobiology. B, Biology 2010; 100(2): 84-91
5. Astulla A, Zaima K, Matsuno Y, Hirasawa Y, Ekasari W, Widyawaruyanti A, Zaini NC, Morita H. Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. Journal of natural medicines (2008); 62(4): 470-72
6. Bensalem S, Soubhye J, Aldib I, Bournine L, Nguyen AT, Vanhaeverbeek M, Rousseau A, Boudjeltia KZ, Sarakbi A, Kauffmann JM, Neve J, Prevost M, Stevigny C, Maiza-Benabdesselam F, Bedjou F, Van Antwerpen P, Duez P. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae). Journal of ethnopharmacology 2014; 154(2): 361-69.
7. El Gendy MA, Somayaji V, El-Kadi AO. Peganum harmala L. is a candidate herbal plant for preventing dioxin mediated effects. Planta medica 2010; 76(7): 671-77.
8. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. Beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2010; 48(3): 839-45.
9. Berrougui H, Isabelle M, Cloutier M, Hmamouchi M, Khalil A. Protective effects of Peganum harmala L. extract, harmine and harmaline against human low-density lipoprotein oxidation. The Journal of pharmacy and pharmacology 2006; 58(7): 967-74.
10. El-Saad El-Rifaie M. Peganum harmala: its use in certain dermatoses. International journal of dermatology 1980; 19(4): 221-22.
11. Kartal M, Altun ML, Kurucu S. HPLC method for the analysis of harmol, harmalol, harmine and harmaline in the seeds of Peganum harmala L. Journal of pharmaceutical and biomedical analysis 2003; 31(2): 263-69.
12. Mina CN, Farzaei MH, Gholamreza A. Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2015; 35(1): 104-9.
13. Dell RB, Holleran S, Ramakrishnan R. Sample size determination. ILAR journal 2002; 43(4): 207-13.
14. Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, Eberhardt NL, Kudva YC. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Laboratory animals 2011; 45(3): 131-40.
15. Alegria-Schaffer A, Lodge A, Vattem K. Performing and optimizing Western blots with an emphasis on chemiluminescent detection. Methods in enzymology 2009; 463: 573-99.
16. Von Wilamowitz-Moellendorff A, Hunter RW, Garcia-Rocha M, Kang L, Lopez-Soldado I, Lantier L, Patel K, Peggie MW, Martinez-Pons C, Voss M, Calbo J, Cohen PT, Wasserman DH, Guinovart JJ, Sakamoto K. Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis. Diabetes 2013 62(12): 4070-82.
17. Kim GY, Lee YM, Cho JH, Pan CJ, Jun HS, Springer DA, Mansfield BC, Chou JY. Mice expressing reduced levels of hepatic glucose-6-phosphatase-alpha activity do not develop age-related insulin resistance or obesity. Human molecular genetics 2015; 24(18): 5115-25.
18. Singh AB, Chaturvedi JP, Narender T, Srivastava AK. Preliminary studies on the hypoglycemic effect of Peganum harmala L. Seeds ethanol extract on normal and streptozotocin induced diabetic rats. Indian journal of clinical biochemistry : IJCB 2008; 23(4): 391-93.
19. Singh AB, Khaliq T, Chaturvedi JP, Narender T, Srivastava AK. Anti-diabetic and anti-oxidative effects of 4-hydroxypipecolic acid in C57BL/KsJ-db/db mice. Human & experimental toxicology 2012; 31(1): 57-65.
20. Komeili G, Hashemi M, Bameri-Niafar M. Evaluation of Antidiabetic and Antihyperlipidemic Effects of Peganum harmala Seeds in Diabetic Rats. Cholesterol 2016; 2016: 7389864.
21. Wang C, Zhang Z, Wang Y, He X. Cytotoxic Constituents and Mechanism from Peganum harmala. Chemistry & biodiversity 2016; 13(7): 961-68.
22. Sreelatha S, Inbavalli R. Antioxidant, antihyperglycemic, and antihyperlipidemic effects of Coriandrum sativum leaf and stem in alloxan-induced diabetic rats. Journal of food science 2012; 77(7): 119-23.
23. Elansary HO, Szopa A, Kubica P, Ekiert H, Al-Mana FA, El-Shafei AA. Polyphenols of Frangula alnus and Peganum harmala Leaves and Associated Biological Activities. Plants 2020; 9(9): 1086.
24. Hadadi Z, Nematzadeh GA, Ghahari S. A study on the antioxidant and antimicrobial activities in the chloroformic and methanolic extracts of 6 important medicinal plants collected from North of Iran. BMC chemistry 2020; 14(1): 33.

XML   Persian Abstract   Print

Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
Volume 25, Issue 6 (Bimonthly 2021) Back to browse issues page